Global Neurovascular Devices Market Set To Grow To $3.3bn By 2022

03 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Neurovascular Devices Market Forecast to 2027 : Cerebral Embolization and Aneurysm Coiling Devices, Cerebral Angioplasty and Stenting Systems, Support Devices, Neurothrombectomy Devices
The neurovascular devices market is segmented into Cerebral Embolization and Aneurysm Coiling Devices, Cerebral Angioplasty and Stenting Systems, Support Devices, and Neurothrombectomy Devices. The market includes products such as clot retrieval devices, microcatheters, guidewires, stent retrievers, aspiration systems, etc.

The lead analyst of the report commented “The neurovascular devices market is driven by aging population, high incidence of obesity, increasing demand for minimally invasive procedures, and growing awareness of neurovascular diseases. In addition, technological advancements to develop new devices will further drive the market growth. The weaknesses of the market include high cost of devices and disadvantages of neurovascular devices.

However, increasing healthcare expenditures to provide better facilities and automated products showcase growing opportunities for the market growth. High cost of R&D activities and alternative medication therapies pose a major threat to the neurovascular devices market.”

Leading companies featured in the report include Stryker Corporation, Medtronic
Johnson & Johnson, Terumo, Penumbra.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Single-Cell Analysis Market Report 2022-2032

The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

26 May 2022

Read

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever